The data demonstrate that intermittent administration of DMB beginning 2 h after infarction continuously modulates ROS and multiple metabolic pathways throughout the course of early remodeling, especially FAO, and this provides novel and valuable insights into the beneficial effects of GLP1 receptor agonism in the heart. Here, GLP1R is linked to infarction.